Anavex Life Sciences is a pharmaceutical company focused on developing novel drug candidates. The company’s ANAVEX 2-73, which is a drug candidate developed to treat Alzheimer’s through disease modification, has completed an initial Phase 1 human clinical trial and was well tolerated in doses up to 55mg. It has been indicated in preclinical studies that ANAVEX 2-73 demonstrates anti-amnesiac and neuroprotective properties. For more information, visit the company’s Web site at www.anavex.com.